Announced
Completed
Financials
Tags
United States
oncology
Pharmaceuticals
Acquisition
Domestic
Public
Friendly
Single Bidder
Majority
Completed
Synopsis
Pathos AI, a clinical stage biotechnology company, completed the acquisition of a 77% stake in Rain Oncology, a precision oncology company. Financial terms were not disclosed. “After a thorough assessment, the Rain Board determined that this Transaction is in the best interests ofour stockholders, as it leverages Rain’s strong cash position to provide a confirmed cash takeout for our stockholders and retains some future potential upside due to Pathos’ continued interest in further developing milademetan for cancer patients using their proprietary PathOS Platform,” Avanish Vellanki, Rain Co-Founder and CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.